Santen SAS

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.santen.eu/fr

Clinical Trials

Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Phase 1

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: NOVA63035 "Corticosteroid"

First Posted Date: 2008-04-23

Last Posted Date: 2015-05-27

Lead Sponsor: Santen SAS

Target Recruit Count: 20

Registration Number: NCT00665106

Locations: 🇺🇸
Midwest Eye Institute, Indianapolis, Indiana, United States

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Phase 2

Completed

Conditions: Conjunctivitis, Vernal

Interventions: Drug: Cyclosporine NOVA22007 0.05%
Drug: Vehicle
Drug: Cyclosporine NOVA22007 0.1%

First Posted Date: 2006-05-22

Last Posted Date: 2021-12-14

Lead Sponsor: Santen SAS

Target Recruit Count: 118

Registration Number: NCT00328653

Locations: 🇫🇷
Groupe Hospitalier Bichat-Claude Bernard, Paris, France

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy